Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

AIDS Clinical Research Projects

Fall 1996

Shared Medical Research
818-345-2172

Hydrea

Study to test the effectiveness of oral hydroxyurea. Patients will be randomized to receive hydroxyurea alone vs. hydroxyurea + ddI + d4T vs. hydroxyurea + ddI. Patients may not have active opportunistic infections.


AIDS Research Alliance
310.358.2429

Advertisement
HGP-30

Phase I study of the therapeutic vaccine HGP-30, a synthetic peptide subunit of HIV antigen p17. Use of approved antivirals other than protease inhibitors allowed. Patients must have T-cell count between 50 and 750. Sergio Codina or Corie Castro.


Pacific Oaks Research
818.906.6279

Viracept/Protease Inhibitor

One year study. All participants will receive open-label Viracept. Must be on antiretroviral therapy and have no prior use of protease inhibitors.

Adefovir Dipivoxil

48 week study of adefovir dipivoxil, a new type of anti-HIV drug that is taken once daily. Participants must currently be tolerating any approved anti-HIV therapy.


USC
213.343.8324

Studies for O.I.'s

A wide variety of clinical Trials are open to women; Prevention and Treatment studies for O.I.'s

La Escuela de asistencia social en la U.S.C. esta llevando a cabo una encuesta de encuesta es completamente confidencial, y se paga $20. llame al 213.740.0299


Kraus Medical Partners
213.930.2324

Salk Vaccine

Enrolling for Salk Vaccine trial.


UCLA Research
310.206.6414

ACTG 293 (women)

Accutane: Phase III study of Accutane (oral isotrentoin) vs. observation for low-grade (CIN-1) cervical dysplasia by comparing the time to progression of CIN-1 to CIN-II, III or invasive cancer. Investigator: Ardis Moe, MD and Suzette Chafey, RN, NP

ACTG 242

Amitriptyline vs. Mexiletine for painful neuropathy.

ACTG 291

Phase II Recombinant Human Nerve Growth Factor for HIV-associated sensory neuropathy: 310.206.6414

Delavirdine

(U-90152S) with ZDV vs. ZDV alone for Patients with CD4 200-500

Nevirapine

(Viramune) vs. placebo, with 3TC and stable nucleoside therapy, CD4 under 200

ALX40-4C

Call UCLA to find out about this drug which blocks certain strains of HIV from penetrating immune cells.

ACTG 242

Amitriptyline vs. Mexiletine for Painful Neuropathy

ACTG 291

Phase II Recombinant Human Nerve Growth Factor for HIV - Associated Sensory Neuropathy.

ACTG 320

Phase III To determine the clinical efficacy of indinavir sulfate or placebo in combination with AZT and 3Tc in AIDS patients


HIV Epidemiology Program
213.351.8195

Acute Infection

Conducting a study on Acute Infection. If you think you might have a recent exposure to HIV, give them a call.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Women Alive. It is a part of the publication Women Alive Newsletter.
 

Tools
 

Advertisement